Profile data is unavailable for this security.
About the company
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
- Revenue in HKD (TTM)6.70bn
- Net income in HKD-9.09bn
- LocationBeigene LtdC/O Mourant Governance Services (Cayman)94 Solaris Avenue, Camana BayBEIJING 102206ChinaCHN
- Phone+1 3 459494123